HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: GelMed

This article was originally published in The Rose Sheet

Executive Summary

GelMed: Bedford, MA-based start-up firm is partnering with "one of the top two" cosmetic firms in the U.S. to develop a product utilizing its Smart Hydrogel delivery system. Developed for cosmetic and medical applications, the polymer is in the form of a liquid when below body temperature but thickens to a gel when it comes in contact with the body. The water-based gel "will set and stick to a pre-determined area of the body allowing for complete and effective treatment," the company states. GelMed says it also is in talks with major cosmetics distributors to find an exclusive partner to disseminate its technology. GelMed, founded in June 1994, develops and commercializes hydrogels for the medical, pharmaceutical, cosmetic, veterinary and consumer industries. To date, the firm has raised $2.2 mil. in seed financing...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001945

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel